北华大学学报（自然科学版）2025，Vol.26Issue(4)：474-479,6.DOI:10.11713/j.issn.1009-4822.2025.04.009
康柏西普两种给药方案治疗糖尿病性黄斑水肿临床疗效
Clinical Efficacy of Two Dosing Regimens of Conbercept in the Treatment of Diabetic Macular Edema
摘要
Abstract
Objective To compare the clinical efficacy of two regimens of vitreous cavity injections of conbercept ophthalmic injection 3+PRN versus 5+PRN in the treatment of diabetic macular edema.Methods 120 patients(120 eyes)with diabetic macular edema(DME)treated with anti-vascular endothelial growth factor(VEGF)in only one eye were selected.The patients were randomly divided into Group A and Group B according to the order of enrollment and personal preference.There were 60 patients(60 eyes)in Group A and 60 patients(60 eyes)in Group B.Patients in Group A received conbercept ophthalmic injections once a month,followed by on-demand injections 3+PRN after 3 consecutive months of treatment.Patients in Group B received conbercept ophthalmic injections once a month,followed by on-demand injections 5+PRN after 5 consecutive months of treatment.All patients were followed up for a period of 1 a after treatment,and the best-corrected visual acuity(BCVA)and central macular thickness(CMT)were compared between the two groups pre-treatment and at 1,3,6,and 12 months post-treatment.In addition,the concentrations of vascular endothelial growth factor(VEGF)and monocyte chemoattractant protein-1(MCP-1)were measured pre-treatment and at 3 and 5 months post-treatment.The number of injections,total number of injections,and incidence of adverse reactions of patients in both groups during PRN treatment were also observed.Results Compared with pre-treatment,BCVA improved and CMT decreased in both groups at 1,3,6,and 12 month post-treatment(both P＜0.05).In particular,at 6 and 12 months post-treatment,BCVA was significantly higher and CMT was significantly lower in Group B compared to Group A(both P＜0.05).At 3 and 5 months post-treatment,VEGF and MCP-1 concentrations in the peripheral blood were significantly lower in both groups compared to pre-treatment(P＜0.05).In addition,at 5 month post-treatment,VEGF and MCP-1 concentrations were significantly lower in Group B than those in Group A(P＜0.05).During the treatment-on-demand(PRN)period,the number of additional injections in Group B was significantly less than that in Group A(P＜0.05).At 12 month postoperatively,the difference in the mean number of injections was not statistically significant when comparing the two groups(P＞0.05).During the follow-up period,no serious adverse reactions were observed in both groups,and all subconjunctival hemorrhages and elevated intraocular pressure had resolved.Conclusion Vitreous cavity injections of conbercept at 3+PRN and 5+PRN were both effective in the treatment of patients with DME.However,the 5+PRN regimen was superior to the 3+PRN regimen in lowering CMT and improving visual acuity.The 5+PRN regimen was also superior to the 3+PRN regimen in reducing the concentrations of VEGF and MCP-1 in peripheral blood.Additionally,the number of additional injections required during the PRN phase was significantly lower for the 5+PRN regimen compared to the 3+PRN regimen.However,there was no significant difference between the two groups in the total number of injections over 1 a.Clinical se-lection of individualized therapeutic regimens should be based on the patient's condition.关键词
康柏西普/糖尿病性黄斑水肿/血管内皮生长因子/单核细胞趋化因子-1Key words
conbercept/diabetic macular edema/vascular endothelial growth factor/monocyte chemoattractant protein-1分类
医药卫生引用本文复制引用
张睿,张富程,石盛玲,桑英旗,冷瀛..康柏西普两种给药方案治疗糖尿病性黄斑水肿临床疗效[J].北华大学学报（自然科学版）,2025,26(4):474-479,6.基金项目
吉林省教育厅科学技术研究项目(JJKH20240095KJ) （JJKH20240095KJ）
吉林省自然科学基金项目(20200201495JC). （20200201495JC）
